Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Authors Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al

Published 16 March 2011 Volume 2011:3 Pages 9—19


Review by Single-blind

Peer reviewer comments 2

This paper has been retracted.
Vinayak W Patil1, Rajeev Singhai1, Amit V Patil2, Prakash D Gurav2
1Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India; 2Department of Surgery, Government Medical College, Miraj, India

Abstract: The aim of our study was to analyze triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER-2/neu) and which represents a subset of breast cancer with different biologic behavior. We investigated the clinicopathological characteristics and prognostic indicators of lymph node-negative TN breast cancer. Medical records were reviewed from patients with node-negative breast cancer who underwent curative surgery at Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, from May 2007 to October 2010. Clinicopathological variables and clinical outcomes were evaluated. Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast cancer. TN breast cancer correlated with younger age (<35 years, P = 0.003) and a higher histopathologic and nuclear grade (P < 0.001). It also correlated with a molecular profile associated with biological aggressiveness: negative for Bcl-2 expression (P < 0.001), positive for the epidermal growth factor receptor (P = 0.003), and a high level of p53 (P < 0.001) and Ki-67 expression (P < 0.00). The relapse rates during the follow-up period (median 56.8 months) were 14.7% for TN breast cancer and 6.6% for non-TN breast cancer (P = 0.004). Relapse-free survival (RFS) was significantly shorter among patients with TN breast cancer compared with those with non-TN breast cancer: 3.5-year RFS rate 85.5% versus 94.2%, respectively; P = 0.001. On multivariate analysis, young age, close resection margin, and triple negativity were independent predictors of shorter RFS. TN breast cancer had a higher relapse rate and more aggressive clinicopathological characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into risk factor analysis for node-negative breast cancer.

Keywords: TN breast cancer, hormone receptors, ER, PgR, HER-2/neu, Ki-67

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other articles by this author:

The p53 breast cancer tissue biomarker in Indian women

Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R

Breast Cancer: Targets and Therapy 2011, 3:71-78

Published Date: 11 August 2011

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women

Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW

Breast Cancer: Targets and Therapy 2011, 3:27-33

Published Date: 19 April 2011

Cancer biomarker HER-2/neu in breast cancer in Indian women

Singhai R, Patil VW, Patil AV

Breast Cancer: Targets and Therapy 2011, 3:21-26

Published Date: 29 March 2011

Readers of this article also read:

Silica nanoparticles increase human adipose tissue-derived stem cell proliferation through ERK1/2 activation

Kim KJ, Joe YA, Kim MK, Lee SJ, Ryu YH, Cho DW, Rhie JW

International Journal of Nanomedicine 2015, 10:2261-2272

Published Date: 24 March 2015

Direct electrochemical oxidation of S-captopril using gold electrodes modified with graphene-AuAg nanocomposites

Pogacean F, Biris AR, Coros M, Lazar MD, Watanabe F, Kannarpady GK, Al Said SA Farha, Biris AS, Pruneanu S

International Journal of Nanomedicine 2014, 9:1111-1125

Published Date: 25 February 2014

Functionalized carbon nanotubes: biomedical applications

Vardharajula S, Ali SZ, Tiwari PM, Eroğlu E, Vig K, Dennis VA, Singh SR

International Journal of Nanomedicine 2012, 7:5361-5374

Published Date: 9 October 2012

Suppression of lung cancer progression by biocompatible glycerol triacrylate– spermine-mediated delivery of shAkt1

Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:2293-2306

Published Date: 4 May 2012


Singhai R

Breast Cancer: Targets and Therapy 2012, 4:33-34

Published Date: 8 March 2012

A triple negative breast cancer: what it is not!

Katakkar SB

Breast Cancer: Targets and Therapy 2012, 4:21-23

Published Date: 24 February 2012

A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting

Zhang L, Zhu WW, Yang CF, Guo HX, Yu AH, Ji JB, Gao Y, Sun M, Zhai GX

International Journal of Nanomedicine 2012, 7:151-162

Published Date: 9 January 2012

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign)

Eric Chen, David M Brown, Matthew S Benz, et al

Clinical Ophthalmology 2010, 4:1151-1158

Published Date: 6 October 2010